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Ventricular assist devices (VADs) were initially pri-
marily used as a bridge to recovery (BTR) for patients 
unable to wean from cardiopulmonary bypass despite 
inotropic support and intra-aortic Balloon pump (IABP) 
[1, 2] and then as a bridge to transplantation (BTT).
Heart transplantation is still the gold standard for the 
treatment of end-stage heart failure patients, but lack of 
donor organs on one hand as well as increasing numbers 
of end-stage HF patients lead to a growing number of 
LVAD implantations (Fig. 1) [3].
In contrast to heart transplantation, left ventricular 
assist devices are available as «off-the-shelf product»; 
therefore, not only they can be implanted as a bridge to 
transplant or in acute settings for patients deteriorating 
on the waiting list, but also as destination therapy (DT) 
for patients too old for transplantation or with contrain-
dications (Fig. 2).
firST-GeneraTiOn lVaDS
The first generation LVADs were designed as a BTT 
only. The first successful transplantation after LVAD 
implantation was performed in 1984 [4]. Over the years, 
miniaturization of the devices created new possibilities: 
more patients could be discharged on VAD, while still 
being listed and awaiting transplantation. However, the 
first generation VADs had several disadvantages: large 
size, noise emission, infections of cannulas and malfunc-
tion induced by tears in the membrane or degradation of 
valves which made everyday life difficult and sometimes 
caused fatal complications [5].
First-generation LVADs were membrane pumps 
either pneumatically or electrically driven, generating 
pulsatile flow with artificial heart valves as inlet and out-
let. Examples are BerlinHeart EXCOR, Thoratec pVAD 
(Fig. 3) and VE/XVE. Connected to the heart via can-
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Fig. 1. Permanent VAD Implantations in Medical University of Vienna
Fig. 2. Heart Transplants and Permanent Assist Devices in Medical University of Vienna. Cardiac Transplants (1984–2015), 
n = 1453; Mechanical Assist Devices (1985–2015), n = 511
      
Fig. 3. The Thoratec pVAD (Thoratec, Pleasanton, CA, USA)
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nulas, these pumps can be used either as isolated left-, 
right- or biventricular VAD (LVAD, RVAD, BiVAD). If 
used for biventricular support, pump chambers have to 
be positioned extracorporeally due to size. For simple left 
ventricular support, intracorporeal placement is possible, 
depending on the type of VAD.
First-generation LVADs available on the market were 
bulky and far too big for any kind of minimally invasive 
surgical approach. Along with the evolution of these 
devices and especially the development of continuous 
flow pumps began the clinical success of VAD surgery.
SecOnD-GeneraTiOn lVaDS
In the 1990s the development of continuous flow cen-
trifugal pump devices improved patient outcome by re-
ducing size of pump and susceptibility for infections. In 
addition, significant noise reduction enhanced the quality 
of life. Designed exclusively for intrathoracic implanta-
tion, their utilization was possible only as LVAD, as the 
devices were too large to be used as BiVAD.
The Thoratec HeartMate II (HMII) is the most suc-
cessful of the second generation LVAD cohort, with over 
20,000 [6] patients supported worldwide (Fig. 4). It is 
a rotary continuous axial flow pump with an external 
electrical power source. Inflow cannula is inserted api-
cally and an outflow graft anastomosed to the ascending 
aorta (in most of the cases) or alternatively to the sub-
clavian artery as bailout strategy. The pump is preload 
dependent and afterload sensitive, runs in a fixed speed 
mode and is capable of up to 10 litres per minute flow 
at a mean aortic pressure of 100 mm mercury (Hg). The 
only moving part is the axial rotor, which spins on ruby 
ball-and-cup bearings, which are continuously washed 
by the flow stream. It is smaller and lighter than the 
HeartMate VE (HMI), offering the possibility of fully 
intrathoracic implantation as well as implantations even 
in small adults. The HMII is typically implanted into a 
properly sized preperitoneal pocket in the left subcostal 
region and utilizes a driveline, which generally exits on 
the upper abdomen.
Nevertheless, a minimally invasive implantation of 
this pump is also feasible; however, the surgical approach 
has to be modified slightly. Instead of a left-sided thora-
cotomy, a subcostal incision is used running along the 
left-sided ribcage (Fig. 5, 6). After division of the abdo-
minal muscles, preparation is performed anteriorly to the 
diaphragm. Through this access, the pericardium can be 
divided and the left ventricular apex is easily identified. 
We are proponents of the running suture technique when 
securing HM II inflow cannula towards the left ventricle; 
however, single stitches may be also used.
Aiming for the subclavian artery as the target vessel 
for outflow graft anastomosis is also feasible in HMII; 
however, due to the design of the device, one has to 
use the right-sided subclavian artery instead of the left 
Fig. 4. Thoratec HeartMate II (Thoratec, Pleasanton, CA, 
USA)
Fig. 5. Left mini-thoracotomy and upper hemisternotomy 
(3rd or 4th ICR)
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(Fig. 7). Exchange of the HeartMate II in case of pump 
thrombosis can also be performed through this access 
if needed [7]. Levin AP et al. described a series of 232 
HeartMate II patients of which 28 required 36 pump 
exchanges. They found 100% survival in their subcos-
tal (minimally invasive) exchanges whereas only 63% 
survived the exchange when performed via sternotomy 
approach, while both groups had the same (high) risk of 
thrombus recurrence (31%).
ThirD-GeneraTiOn lVaDS
The era of intracorporeal continuous flow pumps has 
initiated significant success of LVAD surgery. However, 
median sternotomy has been the only surgical approach 
for implantation over many years. During the last decade, 
the less invasive ways of access gained popularity.
The HeartWare VAD (HVAD) is the centrifugal pump 
which utilizes an innovative combination of passive ma-
gnetic levitation and hydrodynamic suspension to elimi-
nate any contact between the impeller and pump housing 
(Fig. 8). There are no mechanical bearings. The Heart-
Ware is small and designed for completely intrapericar-
dial implantation, with inflow from the left ventricular 
apex and outflow via a graft to the ascending aorta. Like 
other continuous flow pumps it is preload dependent and 
afterload sensitive, operates at a fixed speed mode and is 
capable of delivering up to 10 litres per minute.
There is some evidence that the rate of pump throm-
bosis in HVAD patients could be slightly higher in com-
parison to other contemporary devices. Therefore, some 
centres including our own, started to change the antico-
agulation regimen. At our department we give HeartWare 
patients two doses of 100 mg aspirin daily in addition 
to the standard treatment with phenprocoumon with a 
target INR of 2.5.
The HVAD currently is the smallest CE (Conformité 
Européenne) marked and FDA (US Food and Drug Ad-
ministration) approved pump on the market. Therefore, 
it offers a lot of versatility and possibilities for minimally 
invasive access surgery. In the scientific literature, the 
Fig. 6. Thoratec HeartMate II insertion throught subcostal 
incision
Fig. 7. CT scan reconstruction of outflow graft to the right 
subclavian artery
Fig. 8. HeartWare VAD (HeartWare International Inc, Fra-
mingham, MA, US)
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HVAD system is the device with the most minimally 
invasive implantation experience.
Depending on the surgical requirements and the clini-
cal presentation of the patient, the following minimally 
invasive approaches are feasible:
For isolated LVAD implantation, access to the left 
ventricular apex can be gained through a left-sided ante-
rolateral mini-thoracotomy in the fifth intercostal space 
(Fig. 9); appropriate pump position is verified with TEE 
Fig. 9. Minimally invasive HVAD pump exchange
Fig. 10. Outflow graft anastomosis to the ascending aorta
guidance, and the HVAD sewing ring is secured to the 
left ventricular apex with 4–0 prolene in a running suture 
technique.
Coring of the left ventricle and connection of the 
pump can be performed in the usual manner similar to 
open implantation technique. If the outflow graft is to be 
attached to the ascending aorta, our approach is a right-
sided mini-thoracotomy in the second intercostal space. 
After passing the outflow graft from the left thoracotomy 
towards the right thoracotomy, a side-biting clamp is 
attached on the ascending aorta. After adequate incision 
of the aorta, the graft is anastomosed in the usual manner 
(Fig. 10). Finally, the driveline is tunneled into the right 
upper quadrant of the abdomen.
Our own group published the initial results of the first 
27 patients implanted via a less invasive bilateral thora-
cotomy approach. This series showed rather promising 
results in a cohort of 85% male patients, 29% Intermacs I, 
and 22% redo surgeries, and there was a 30-day mortality 
of 7.5% with no postoperative RV failure, three patients 
(11%) underwent surgical revision for bleeding, and one 
(4%) pump thrombosis [8].
Alternatively to the right-sided thoracotomy, some 
centers prefer a hemi-sternotomy access for the outflow 
graft anastomosis. This technique was described by 
Schmitto et al. in 2012.
At our center, we use this approach if additional pro-
cedures are necessary: in case of an additional aortic 
valve replacement, we opt for a hemi-sternotomy in the 
third intercostal space, and in case of an additional tri-
cuspid repair, we aim for the fourth intercostal space.
For anastomosis of the outflow graft, different target 
vessels beside the ascending aorta can be suitable. One 
promising target vessel might be the subclavian artery. 
In case of minimally invasive HVAD implantation, the 
previously described technique can be used in a similar 
way. However, there is no need for a second thoracotomy 
since a left-sided incision two centimeters below the left 
clavicle is used similar to an incision for a pacemaker 
implantation. After identification and preparation of the 
subclavian artery, the outflow graft is tunneled through 
the second intercostal space. It is recommended to en-
large the interspace and to cover the outflow graft with 
an additional Gore-Tex prosthesis at the area passing the 
ribcage in order to avoid the graft kinking.
Before anastomosing the outflow graft, a suitable 
position on the inferior side of the subclavian artery is 
identified. After performing the anastomosis and the es-
tablishment of the LVAD flow, a banding distal to the 
anastomosis is attached around the subclavian artery 
aiming for equal blood pressure levels in both arms [9].
The subclavian approach seems very appealing in 
cases of severe calcification of the ascending aorta; also, 
VAD implantation in redo scenarios can be facilitated 
thus avoiding re-sternotomy. However, there are con-
cerns regarding hyperperfusion of the arm and issues 
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While within the CE mark trial, the 30-day survi-
val rate was excellent with 98% and the rate of adverse 
events (bleeding 30%, arrhythmia 28%, infections 20%, 
strokes 4%) was throughout comparable to other con-
temporary devices. Especially, the 0% pump-thrombosis 
rate appears promising [10].
The profile of the pump is a little higher than the 
profile of the HVAD and the sewing ring is different. 
However, in minimally invasive implantation, techniques 
similar to the described HVAD implantation can be used 
(Fig. 12).
To implant the pump through a left-sided thoraco-
tomy, a slightly greater incision than for the HVAD 
implantation is recommended; however, there are also 
special instruments under development facilitating the 
implantation of this pump through this access. Due to the 
different designs of the sewing ring, we recommend 2–0 
prolene in a running suture technique. For anastomosis 
of the outflow graft, the techniques and approaches pre-
viously described in less invasive HVAD implantation 
can be used here in same fashion.
HeartWare MVAD (Fig. 13) is a continuous axial flow 
pump, approximately one-third the size of the HVAD. 
Fig. 13. HeartWare MVAD (HeartWare International Inc, 
Framingham, MA, US)
Fig. 11. Thoratec HeartMate III (Thoratec, Pleasanton, CA, 
USA)
Fig. 12. View of Thoratec HeartMate III through a left-sided 
thoracotomy
Table
Minimally invasive implantation techniques overview




or left thoracotomy + left 
A. subclavia
Subcostal incision + right 
thoracotomy or right 
A. subclavia
Bilateral mini-thoracotomy 
or left thoracotomy + left 
A. subclavia
Circulatory support ECMO or off pump or CPB CPB CPB
LVAD + AVR:
Surgical access
Left mini-thoracotomy + upper 
hemisternotomy (3rd ICR)
Subcostal incision + upper 
hemisternotomy (3rd ICR)
Left mini-thoracotomy + upper 
hemisternotomy (3rd ICR)
Circulatory support CPB CPB CPB
+ LVAD + TK-repair ± AVR:
Surgical access
Left mini-thoracotomy + upper 
hemisternotomy (4th ICR)
Subcostal incision + upper 
hemisternotomy (4th ICR)
Left mini-thoracotomy + upper 
hemisternotomy (4th ICR)
Circulatory support CPB CPB CPB
related to a mismatch between the diameter of the out-
flow graft and the size of the target vessel which might 
be predisposing for pump thrombosis.
HeartMate III (Fig. 11) is the latest CE marked conti-
nuous flow LVAD device on the market. It is especially 
appealing due to promising low rates of pump thrombosis 
in the CE mark trial.
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TheraPY fOr PulMOnarY hYPerTenSiOn 
(The Vienna MODel)
LVAD support, when used as a BTT, effectively im-
proves pulmonary hemodynamics in patients with end-
stage heart failure. Pulmonary hypertension is a common 
complication of severe long-standing heart failure. Ap-
proximately 72% of patients with terminal heart failure 
who are eligible for cardiac transplantation have PH 
(Fig. 14) [14].
cOncluSiOn
Vienne strategy is a distribution of patients in two 
groups: the heart transplant recipients and patients re-
ceiving LVADs as a BTT. The second group included 
patients approved and listed for transplant, patients who 
are unable to survive until transplantation without VAD, 
patients who might profit from VAD therapy (rehabilita-
tion). Balance between LVAD and heart transplantation 
depended on: infrastructure of the center; law (informed 
or presumed consent); the individual risk of the patient.
The authors declare no conflict of interest.
referenceS
1. Milano CA, Simeone AA. Mechanical circulatory sup-
port: devices, outcomes and complications. Heart Fail 
Rev. 2013; 18: 35–53.
Fig. 14. Pharmacologic testing: decision-making tree. TX, Transplant; PVR, pulmonary vascular resistance; WU, Wood units; 
PG, prostaglandin; NO, nitric oxide; LVAD, left ventricular assist device
The MVAD is based on the same proprietary ‘contact-
less’ impeller suspension technology used in the HVAD, 
with its single moving part held in place through a com-
bination of passive magnetic and hydrodynamic forces. 
In vitro and in vivo studies showed promising results. 
Within one in vivo study the MVAD was implanted in an 
ovine model (n = 9) for 90 days. Results demonstrated 
the safety, reliability, hemocompatibility, and biocompa-
tibility of the MVAD. Nine animals were implanted for 
90 ± 5 days. No complications occurred during surgical 
implantation. Seven of the nine animals survived until 
elective sacrifice. Each sheep that survived to the sche-
duled explant appeared physically normal, with no signs 
of cardiovascular or other organ compromise. Even a 
transapical implantation approach was tested [13]. A new 
cannula configuration has been developed for transapical 
implantation, where the outflow cannula is positioned 
across the aortic valve. The two primary objectives for 
this feasibility study were to evaluate anatomic fit and 
surgical approach, and efficacy of the transapical MVAD 
configuration. Anatomic fit and surgical approach were 
demonstrated using human cadavers (n = 4). Efficacy 
was demonstrated in acute (n = 2) and chronic (n = 1) bo-
vine model experiments and assessed by improvements 
in hemodynamics, biocompatibility, flow dynamics, and 
histopathology. Potential advantages of the MVAD pump 
include flow support in the same direction as the native 
ventricle; elimination of cardiopulmonary bypass, and 
minimally invasive implantation.
141
ПО мАТЕРИАЛАм IX ВСЕРОССИйСКОГО СъЕЗдА ТРАНСПЛАНТОЛОГОВ
2. Pierce WS, Parr GV, Myers JL et al. Ventricular-assist 
pumping patients with cardiogenic shock after cardiac 
operations. N Engl J Med. 1981; 305: 1606–1610.
3. Lund H, Edwards LB, Kucheryavaya AY et al. The Re-
gistry of the International Society for Heart and Lung 
Transplantation: Thirty-second Official Adult Heart 
Transplantation Report – 2015; Focus Theme: early graft 
failure. J Heart Lung Transplant. 2015; 34: 1244–1254.
4. Portner PM, Oyer PE, McGregor CG et al. First human 
use of an electrically powered implantable ventricular 
assist system. Artif Organs. 1985; 936–941.
5. Prinzing A, Herold U, Berkefeld A, Krane M, Lange R, 
Voss B. Left ventricular assist devices – current state and 
perspectives. J Thorac Dis. 2016; 8 (8): E660–E666.
6. Kirklin JJ, Pagani F, Kormos R et al. Eighth annual IN-
TERMACS report: special focus on framing the impact 
of adverse events. J Heart Lung Transplant. 2017; 36: 
1080–1086.
7. Levin AP, Uriel N, Takayama H et al. Device exchange 
in HeartMate II recipients: long-term outcomes and risk 
of thrombosis recurrence. ASAIO. 2015; 61: 144–149.
8. Haberl T, Riebandt J, Mahr S et al. Viennese approach 
to minimize the invasiveness of ventricular assist device 
implantation. Eur J Cardiothorac Surg. 2014; 46: 991–
996.
9. Riebandt J, Haberl T, Mahr S et al. Off-Pump HeartWare 
ventricular assist device implantation with outflow graft 
anastomosis to the left subclavian artery. Ann Thorac 
Surg. 2013; 97: 2214–2216.
10. Zimpfer D, Netuka I, Schmitto JD et al. Multicentre cli-
nical trial experience with the HeartMate 3 left ventricu-
lar assist device: 30-day outcomes. Eur J Cardiothorac 
Surg. 2016; 50: 548–554.
11. Mehra MR, Naka Y, Uriel N et al. A fully magnetically 
levitated circulatory pump for advanced heart failure. N 
Engl J Med. 2017; 376: 440–450.
12. McGee E Jr, Chorpenning K, Brown MC et al. In vivo 
evaluation of the HeartWare MVAD Pump. J Heart Lung 
Transplant. 2014; 33: 366–371.
13. Tamez D, LaRose JA, Shambaugh C et al. Early feasibi-
lity testing and engineering development of the transapi-
cal approach for the HeartWare MVAD ventricular assist 
system. ASAIO J. 2014; 60: 170–177.
14. Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, 
Huber L et al. Left ventricular assist devices decrease 
fixed pulmonary hypertension in cardiac transplant can-
didates. J Thorac Cardiovasc Surg. 2007; 133 (3): 689–
695.
Статья поступила в редакцию 28.09.2018 г.
The article was submitted to the journal on 28.09.2018
